Skip to content
Privacy Policy | Cookie Policy | LinkedIn

Rare Disease Therapeutics

Innovating in rare disease

We make a meaningful contribution to the lives of rare disease patients and their families

Scroll to explore

We champion accessibility to rare disease medicines

Helping more patients access established medicines

Bringing innovative new medicines to patients in need

Why Oranda

Uniquely Oranda

Founded on Partnership

Founded on Partnership

Oranda is a company founded on partnership. We're entrepreneurial and agile, with a focus on delivering value to patients, our customers and partners.

The Oranda

The Oranda

Our company is named after the Oranda, a rare breed of goldfish symbolising longevity, adaptability, personal growth and the pursuit of fulfilment.

Beauty in Difference

Beauty in Difference

The Oranda serves as a reminder that everyone is unique and can live positive and purposeful lives. Beauty lies in our differences.

WHAT WE DO

How We Create Access

01

Our Approach

We are dedicated to securing sustainable access to rare disease medicines across Europe, initially through the provision of affordable, high quality, essentially similar versions of established medicines.

Discover Our Approach
02

Our Focus

We are focused on identifying and addressing the needs of those living with hereditary amyloidosis, cystic fibrosis and idiopathic pulmonary fibrosis.

Explore Our Focus
03

Collaboration

We collaborate with system stakeholders, to identifying and address access barriers to ensure our medicines reach those who may benefit from them.

Partner With Us

FAQ

Common questions

Oranda is a rare disease company dedicated to improving sustainable access to established and innovative new medicines across Europe.

Our current focus is on rare cardio-respiratory conditions, specifically idiopathic pulmonary fibrosis, hereditary amyloidosis and cystic fibrosis however we are committed in addressing unmet need in rare disease and consider ourselves therapy area agnostic.

Today fewer than half of all EMA approved innovative medicines are available to rare disease patients throughout Europe, with medicine affordability remaining acritical barrier to healthcare access. Oranda is committed to addressing this access issue through the provision of affordable, high quality, essentially similar versions of established rare disease medicines on Loss of Exclusivity (LoE).

Yes, we partner with organisations that value efficiency, ethical working, and long-term patient impact. Companies benefit from our commercial flexibility and resourceful ways of working.

Oranda Therapeutics is registered in Ireland with offices at Wicklow House, Market Square, Wicklow, Co. Wicklow, A67 W589.

Visit our Contact page to reach us about our corporate strategy, investment or partnership opportunities.

Ready to Partner?

Whether you're an investor, potential partner, healthcare professional, or journalist, we'd love to hear from you.

Get in Touch

OTD-NP-GBR-00001 | March 2026